Literature DB >> 22181069

Eucommia ulmoides bark protects against renal injury in cadmium-challenged rats.

Erwei Liu1, Lifeng Han, Jialong Wang, Wei He, Haihua Shang, Xiumei Gao, Tao Wang.   

Abstract

Eucommia ulmoides Oliver is a perennial woody plant distributed widely in China. To characterize some major compounds in E. ulmoides bark extract, six compounds were identified via high-performance liquid chromatography qualitative analysis. E. ulmoides bark extract protects against cadmium-induced oxidative damage in rat kidneys. Two compounds of E. ulmoides bark extract, geniposide and genipin, which were identified both in serum and in kidney tissue, showed inhibitory effects on nitric oxide production. This study provides biological evidence supporting the usefulness of E. ulmoides bark against cadmium-induced toxic oxidative stress in rat kidney tissue.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22181069     DOI： 10.1089/jmf.2011.1756

Source DB:  PubMed          Journal:  J Med Food        ISSN： 1096-620X            Impact factor:   2.786


  11 in total

1.  Exploring the biomarkers and therapeutic mechanism of kidney-yang deficiency syndrome treated by You-gui pill using systems pharmacology and serum metabonomics.

Authors:  Ruiqun Chen; Jia Wang; Chengbin Liao; Lei Zhang; Qian Guo; Xiufeng Wang
Journal:  RSC Adv       Date:  2018-01-03       Impact factor: 4.036

2.  Effect of Eucommia ulmoides leaves on hyperuricemia and kidney injury induced by a high-fat/high-fructose diet in rats.

Authors:  Man Gong; Hong Zhang; Xiaoqian Liu; Qingxia Li; Yang Zhang; Weijin Zhang; Na Huang; Anying Chen; Liping Dai; Zhimin Wang
Journal:  Iran J Basic Med Sci       Date:  2022-04       Impact factor: 2.532

3.  Eucommia ulmoides Oliv. (Du-Zhong) Lignans Inhibit Angiotensin II-Stimulated Proliferation by Affecting P21, P27, and Bax Expression in Rat Mesangial Cells.

Authors:  Xian Jing; Wei-Hua Huang; Yong-Jun Tang; Ya-Qin Wang; Hui Li; Ying-Ying Tian; Yao Chen; Hong-Hao Zhou; Dong-Sheng Ouyang
Journal:  Evid Based Complement Alternat Med       Date:  2015-06-10       Impact factor: 2.629

4.  Pinoresinol Diglucoside Alleviates oxLDL-Induced Dysfunction in Human Umbilical Vein Endothelial Cells.

Authors:  Jinpeng Yao; Zhipeng Zou; Xiangfen Wang; Xiaoping Ji; Jun Yang
Journal:  Evid Based Complement Alternat Med       Date:  2016-11-30       Impact factor: 2.629

Review 5.  Cadmium-Induced Kidney Injury: Oxidative Damage as a Unifying Mechanism.

Authors:  Liang-Jun Yan; Daniel C Allen
Journal:  Biomolecules       Date:  2021-10-23

6.  Lignans from the bark of Eucommia ulmoides inhibited Ang II-stimulated extracellular matrix biosynthesis in mesangial cells.

Authors:  Zhen-Yu Li; Xiao-Lan Deng; Wei-Hua Huang; Ling Li; Hui Li; Xian Jing; Ying-Ying Tian; Pei-Yu Lv; Tian-Lun Yang; Hong-Hao Zhou; Dong-Sheng Ouyang
Journal:  Chin Med       Date:  2014-02-14       Impact factor: 5.455

7.  Eucommia bark (Du-Zhong) improves diabetic nephropathy without altering blood glucose in type 1-like diabetic rats.

Authors:  Ho-Shan Niu; I-Min Liu; Chiang-Shan Niu; Po-Ming Ku; Chao-Tien Hsu; Juei-Tang Cheng
Journal:  Drug Des Devel Ther       Date:  2016-03-02       Impact factor: 4.162

8.  The Anti-Inflammatory Activity of Eucommia ulmoides Oliv. Bark. Involves NF-κB Suppression and Nrf2-Dependent HO-1 Induction in BV-2 Microglial Cells.

Authors:  Seung-Hwan Kwon; Shi-Xun Ma; Ji-Young Hwang; Yong-Hyun Ko; Ji-Yeon Seo; Bo-Ram Lee; Seok-Yong Lee; Choon-Gon Jang
Journal:  Biomol Ther (Seoul)       Date:  2016-05-01       Impact factor: 4.634

Review 9.  Health-Promoting Properties of Eucommia ulmoides: A Review.

Authors:  Tarique Hussain; Bi'e Tan; Gang Liu; Oso Abimbola Oladele; Najma Rahu; M C Tossou; Yulong Yin
Journal:  Evid Based Complement Alternat Med       Date:  2016-03-02       Impact factor: 2.629

10.  Antihypertensive Activity of Eucommia Ulmoides Oliv: Male Flower Extract in Spontaneously Hypertensive Rats.

Authors:  Zhen-Jiang Ding; Chao Liang; Xiao Wang; Xin Yao; Ruo-Han Yang; Zhan-Sheng Zhang; Jin-Jin He; Hong-Yan Du; Dong Fang; Qin Li
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-30       Impact factor: 2.629
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.